Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, has announced it will report its first fiscal quarter 2025 financial results on Tuesday, August 6, 2024, after the market closes. The company focuses on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors (through its affiliate Beyond Cancer, ). The financial results will cover the period ended June 30, 2024.
Beyond Air (NASDAQ: XAIR), un'azienda di dispositivi medici e biopharmaceutici in fase commerciale, ha annunciato che riporterà i suoi risultati finanziari del primo trimestre fiscale 2025 martedì 6 agosto 2024, dopo la chiusura del mercato. L'azienda si concentra sull'utilizzo del potere dell'ossido nitrico (NO) endogeno ed esogeno per migliorare la vita dei pazienti affetti da malattie respiratorie, disturbi neurologici e tumori solidi (attraverso la sua affiliata Beyond Cancer). I risultati finanziari copriranno il periodo terminato il 30 giugno 2024.
Beyond Air (NASDAQ: XAIR), una empresa de dispositivos médicos y biopharma en etapa comercial, ha anunciado que reportará sus resultados financieros del primer trimestre fiscal 2025 el martes 6 de agosto de 2024, después del cierre del mercado. La empresa se centra en aprovechar el poder del óxido nítrico (NO) endógeno y exógeno para mejorar la vida de los pacientes con enfermedades respiratorias, trastornos neurológicos y tumores sólidos (a través de su afiliada Beyond Cancer). Los resultados financieros cubrirán el período que concluyó el 30 de junio de 2024.
비욘드 에어 (NASDAQ: XAIR)는 상용화 단계의 의료기기 및 생물의약품 회사로, 2025 회계연도 첫 분기 재무 결과를 2024년 8월 6일 화요일 시장 종가 이후에 발표할 것이라고 발표했습니다. 회사는 호흡기 질환, 신경 장애 및 고형 종양으로 고통받는 환자들의 삶을 개선하기 위해 내인성 및 외인성 질산화물(NO)의 힘을 활용하는 데 집중하고 있습니다 (자회사의 비욘드 캔서(Beyond Cancer)를 통해). 재무 결과는 2024년 6월 30일에 종료된 기간을 포함합니다.
Beyond Air (NASDAQ: XAIR), une entreprise de dispositifs médicaux et de biopharmaceutiques en phase commerciale, a annoncé qu'elle publiera ses résultats financiers du premier trimestre fiscal 2025 le mardi 6 août 2024, après la fermeture des marchés. L'entreprise se concentre sur l'utilisation du pouvoir de l'oxyde nitrique (NO) endogène et exogène pour améliorer la vie des patients souffrant de maladies respiratoires, de troubles neurologiques et de tumeurs solides (via sa filiale Beyond Cancer). Les résultats financiers couvriront la période se terminant le 30 juin 2024.
Beyond Air (NASDAQ: XAIR), ein kommerziell tätiges Unternehmen für Medizingeräte und biopharmazeutische Produkte, hat angekündigt, dass es am Dienstag, den 6. August 2024, nach Börsenschluss seine Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 veröffentlichen wird. Das Unternehmen konzentriert sich darauf, die Kraft von endogenem und exogenem Stickstoffmonoxid (NO) zu nutzen, um das Leben von Patienten mit Atemwegserkrankungen, neurologischen Störungen und soliden Tumoren (über seine Tochtergesellschaft Beyond Cancer) zu verbessern. Die Finanzergebnisse decken den Zeitraum bis zum 30. Juni 2024 ab.
- Company is maintaining regular financial reporting schedule, indicating operational continuity
- Beyond Air has reached commercial stage, suggesting potential revenue generation
- None.
GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it will report financial results for its first fiscal quarter 2025 ended June 30, 2024 on Tuesday, August 6, 2024 after the market closes.
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Air (XAIR) report its Q1 2025 financial results?
What is the fiscal period covered in Beyond Air's (XAIR) upcoming financial report?
What are the main focus areas of Beyond Air (XAIR)?
Is Beyond Air (XAIR) a commercial stage company?
